Source comparison
BPC-157 Studied Diabetic Neuropathy Research: Comparison
BPC-157 VEGF upregulation + anti-inflammatory cytokine modulation 28–34% improvement in sciatic nerve conduction velocity at 10–100 mcg/kg over 21–28 days (rat models) 41% reduction in TNF-alpha, significant IL-6 reduction No human trials for diabetic neuropat
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation + anti-inflammatory cytokine modulation
- 28–34% improvement in sciatic nerve conduction velocity at 10–100 mcg/kg over 21–28 days (rat models)
- 41% reduction in TNF-alpha, significant IL-6 reduction
- No human trials for diabetic neuropathy; preclinical only
- Strongest preclinical evidence for nerve regeneration via angiogenesis; human translation uncertain due to dose scaling challenges
- Cerebrolysin (peptide mix)
- Neurotrophic factor mimicry (BDNF, NGF pathways)
- 15–22% improvement in motor nerve conduction in diabetic rats
- Moderate oxidative stress marker reduction
- Phase II trials in diabetic polyneuropathy showed modest symptom improvement but no FDA approval
- Established safety profile in humans but limited efficacy in metabolic neuropathy versus stroke recovery
- Alpha-lipoic acid
- Antioxidant (reduces oxidative stress from hyperglycemia)
- 10–18% improvement in sensory nerve conduction (human trials)
- Moderate reduction in lipid peroxidation markers
- Available as supplement; used off-label in Europe for diabetic neuropathy
- Only antioxidant with meaningful clinical trial data in diabetic neuropathy; effect size modest but reproducible
- Acetyl-L-carnitine
- Mitochondrial support + nerve growth factor modulation
- 12–19% improvement in nerve conduction velocity (human trials)
- Minimal direct anti-inflammatory effect
- Discontinued in Phase III trials due to inconsistent outcomes
- Early promise not sustained in larger trials; mechanism insufficient for established neuropathy